Avidity Biosciences News

Avidity Biosciences Analyst Ratings

BenzingaMay 10 18:59

Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target

BenzingaMay 10 19:00

Needham: Reiterates Avidity Biosciences (RNA.US) rating and adjusted from buy to buy rating, target price is $35.00.

Zhitong FinanceMay 10 19:03

Analysts Offer Insights on Healthcare Companies: Avidity Biosciences (RNA) and Curaleaf Holdings (OtherCURLF)

TipRanksMay 10 17:30

Buy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory Advancements

TipRanksMay 9 17:17

Avidity Biosciences (RNA.US) was first covered by B of A Securities, which gave it a buy rating, with a target price of $40.00.

Zhitong FinanceMay 3 18:20

Avidity Biosciences Analyst Ratings

BenzingaMay 3 18:17

B of A Securities Initiates Coverage On Avidity Biosciences With Buy Rating, Announces Price Target of $40

BenzingaMay 3 18:18

Avidity Biosciences Analyst Ratings

BenzingaApr 11 19:21

Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)

TipRanksApr 11 18:40

Avidity Biosciences Analyst Ratings

BenzingaMar 14 19:35

Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge

TipRanksMar 7 12:25

Optimistic Buy Rating for Avidity Biosciences Backed by Promising Phase 3 Study Design and Positive MARINA OLE Data

TipRanksMar 5 18:02

Analysts' Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)

TipRanksMar 5 18:01

Buy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA Analysis

TipRanksMar 5 10:36

Avidity Biosciences Analyst Ratings

BenzingaMar 5 02:09

Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)

TipRanksFeb 29 20:11

TD Cowen Reaffirms Their Buy Rating on Avidity Biosciences (RNA)

TipRanksFeb 29 11:05

Buy Rating on Avidity Biosciences Amid Promising Clinical Milestones

TipRanksJan 10 18:41

Wells Fargo Reiterates Overweight on Avidity Biosciences, Maintains $50 Price Target

BenzingaJan 4 02:11